双膦酸盐对大鼠颌面骨及外周骨不同来源骨髓间充质干细胞成骨分化的影响

doi:10.3969/j.issn.1005-4979.2016.04.003

《口腔颌面外科杂志》 ›› 2016, Vol. 26 ›› Issue (4): 244-250. doi: 10.3969/j.issn.1005-4979.2016.04.003

双膦酸盐对大鼠颌面骨及外周骨不同来源骨髓间充质干细胞成骨分化的影响

俞宛璐，苏俭生

同济大学口腔医学院·同济大学附属口腔医院修复教研室，上海牙组织修复与再生工程技术研究中心，上海 200072

收稿日期:2016-03-08 修回日期:2016-03-16 出版日期:2016-08-28 发布日期:2016-09-24
通讯作者: 苏俭生，教授. E-mail: sjs@tongji.edu.cn
作者简介:俞宛璐（1989—），女，上海人，博士研究生. E-mail: vivian_yuwanlu@hotmail.com
基金资助:
国家自然科学基金（81371949,81572114）；上海市科学技术委员会医学重点项目（13411951201）；教育部博士点基金（20110072110041）

Effect of Bisphosphonates on Osteogenic Potential of Mandibular vs. Long-bone Mesenchymal Stem Cells in Rats

YU Wan-lu, SU Jian-sheng

Department of Prothodontics, School and Hospital of Stomatology, Tongji University, Shanghai Engineering Research Center of Tooth Regeneration, Shanghai 200072, China

Received:2016-03-08 Revised:2016-03-16 Online:2016-08-28 Published:2016-09-24

摘要/Abstract

摘要： 目的：研究临床常用第三代双膦酸盐——唑来膦酸，对大鼠颌面骨及外周骨两种来源的骨髓间充质干细胞(BMSCs)增殖及成骨分化的影响。方法：从新生SD大鼠中分离和培养颌骨或髂骨来源的BMSCs，观察不同浓度唑来膦酸对2种来源BMSCs的影响。观察较高浓度的唑来膦酸对这2种细胞碱性磷酸酶活性、骨钙素分泌的影响。结果：髂骨来源的BMSCs在唑来膦酸浓度≥2.0 μg/mL时增殖受到抑制，浓度≤1.0 μg/mL时增殖不受影响。而颌骨来源的BMSCs，当唑来膦酸浓度≥0.5 μg/mL时细胞增殖就已受到明显的抑制。较高浓度的唑来膦酸（1.0 μg/mL）可抑制颌骨BMSCs碱性磷酸酶的活性以及骨钙素形成；但此浓度，对于髂骨BMSCs碱性磷酸酶活性、骨钙素的形成并没有明显的影响。结论：双膦酸盐对不同来源的BMSCs增殖和成骨分化的影响有差异，可为探索双膦酸盐相关颌骨坏死的发病机制提供理论基础。

关键词: 双膦酸盐, , , 颌骨, , , 髂骨, , , 骨髓间充质干细胞, , , 增殖, , , 成骨分化

Abstract: Objective: To investigate the effects of zoledronate， a third generation of bisphosphonates commonly used in clinical practice，on the proliferation and osteogenic differentiation potential of mandibular and long-bone mesenchymal stem cells (BMSCs) in rats. As well as, to study the discrepancy of drug response to biological characteristics of cells derived from distinct skeletal sites. Methods: The BMSCs isolated from the mandible and ilium bone of SD newborn rats were cultured with different concentrations of zoledronate. At 3 days after zoledronate exposure, Alarmar Blue assay was used to measure the absorbance to determine the effect of zoledronate on the proliferation of mandible and ilium mesenchymal stem cells. Cell alkaline phosphatase activity and osteocalcin secretion of mandible and ilium BMSCs were analyzed. Results: Zoledronate at the concentration of ≥2.0 μg/mL could inhibit the proliferation of ilium BMSCs, but it had no effect at the concentration of ≤1.0 μg/mL. For mandible BMSCs, zoledronate at the concentration of ≤0.5 μg/mL inhibited the cell proliferation significantly. Zoledronate (1.0 μg/mL) could also inhibit cell alkaline phosphatase activity, osteocalcin secretion of mandible BMSCs, but at the same concentration, it had no effect to ilium BMSCs. Conclusion: Our findings support that function and differentiation potential of BMSCs derived from distinct origins after exposure to zoledronate is discrepant, and provide a new theoretical basis to clarify pathogenesis of bisphosphonates related osteonecrosis of the jaw (BRONJ).

Key words: bisphosphonates, mandible, ilium, bone mesenchymal stem cells, proliferation, osteogenic differentiation

中图分类号:

R782
Q813.1

俞宛璐，苏俭生. 双膦酸盐对大鼠颌面骨及外周骨不同来源骨髓间充质干细胞成骨分化的影响[J]. 《口腔颌面外科杂志》, 2016, 26(4): 244-250.

YU Wan-lu, SU Jian-sheng. Effect of Bisphosphonates on Osteogenic Potential of Mandibular vs. Long-bone Mesenchymal Stem Cells in Rats[J]. 《Journal of Oral and Maxillofacial Surgery》, 2016, 26(4): 244-250.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2016/V26/I4/244

参考文献

[1] Seton M. Paget disease of bone: diagnosis and drug therapy[J]. Cleve Clin J Med, 2013, 80(7):452-462.

[2] Knauer M, Thürlimann B. Adjuvant bisphosphonates in breast cancer treatment[J]. Breast Care (Basel), 2014, 9(5):319-322.

[3] Oida T, Mimatsu K, Kano H, et al. Administration of bisphosphonates for malignant hepatic tumor with hypercalcemia[J]. Hepatogastroenterology, 2012, 59(114):444-447.

[4] Pazianas M, Abrahamsen B. Safety of bisphosphonates[J]. Bone, 2011, 49(1):103-110.

[5] Biswas PN, Wilton LV, Shakir SA. Pharmacovigilance study of alendronate in England[J]. Osteoporos Int, 2003, 14(6):507-514.

[6] Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use[J]. N Engl J Med, 2009, 360(1):89-90.

[7] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117.

[8] Vescovi P, Merigo E, Meleti M, et al. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients[J]. J Oral Pathol Med, 2012, 41(3):214-221.

[9] Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview[J]. Ann N Y Acad Sci, 2011, 1218:38-46

[10] McLeod NM, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review[J]. Surgeon, 2012, 10(1):36-42.

[11] Hasegawa T, Ri S, Umeda M, et al. The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy[J]. J Craniomaxillofac Surg, 2013, 41(7):558-563.

[12] Ruggiero SL, Dodson TB, Assael LA, et al. American Association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update[J]. J Oral Maxillofac Surg, 2009, 67(Suppl 1):2-12.

[13] Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases[J]. Oral Oncol, 2006, 42(3):327-329.

[14] Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper[J]. J Am Dent Assoc, 2005, 136(12):1658-1668.

[15] Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease[J]. Aust Dent J, 2005, 50(4 Suppl 2):S4-13.

[16] Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis(bis-phossyjaw): is this phossy jaw of the 21st century[J]? J Oral Maxillofac Surg, 2005, 63(5):682-689.

[17] Helms JA, Schneider RA. Cranial skeletal biology[J]. Nature, 2003, 423(6937):326-331.

[18] Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation[J]. Cell, 2002, 108(1):17-29.

[19] Reilly GC, Radin S, Chen AT, et al. Differential alkaline phosphatase responses of rat and human bone marrow derived mesenchymal stem cells to 45S5 bioactive glass[J]. Biomaterials, 2007, 28(28):4091-4097.

[20] 龚雪, 苏俭生. 唑来膦酸对大鼠颌骨间充质干细胞成骨分化的影响[J]. 口腔颌面外科杂志, 2015, 25(1):28-33.

[21] 赵航, 苏俭生. 双膦酸盐致相关性颌骨坏死的研究进展[J]. 口腔颌面外科杂志, 2013, 23(1):72-76.

[22] Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases[J]. J Oral Maxillofac Surg, 2004, 62:527-534.

[23] Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy[J]. Cancer, 2005, 104(1):83-93.

[24] Abu-Id MH, Warnke PH, Gottschalk J, et al. "Bisphossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2008, 36(2):95-103.

[25] Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats[J]. Cancer Res, 2002, 62(22):6538-6544.

[26] Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells[J]. Bone, 2008, 42(5):848-860.

[27] 黄婉兰．双膦酸盐抗血管形成机制研究进展[J]．国际肿瘤学杂志, 2010, 37(11):831-835.

[28] Ravosa MJ, Ning J, Liu Y, et al. Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts[J]. Arch Oral Biol, 2011, 56(5):491-498.

[29] Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis [J]. J Oral Pathol Med, 2006, 35(3):155-160.

[30] Stefanik D,Sarin J. Disparate osteogenic response of mandible and iliac crest bonemarrow stromal cells to pamidronate[J]. Oral Dis, 2008, 14(5):465-471.

选择文件类型/文献管理软件名称

选择包含的内容

双膦酸盐对大鼠颌面骨及外周骨不同来源骨髓间充质干细胞成骨分化的影响

Effect of Bisphosphonates on Osteogenic Potential of Mandibular vs. Long-bone Mesenchymal Stem Cells in Rats

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡娟. 游离组织瓣修复颌面部缺损后血管蒂骨化的发生率及影响因素的系统评价[J]. 《口腔颌面外科杂志》, 2023, 33(6): 379-384.
[2]	肖晨亮, 孙丽君, 何晓清, 徐路, 赵徐达. 三维打印+膜诱导技术修复重建下颌骨节段性缺损1例报道[J]. 《口腔颌面外科杂志》, 2023, 33(6): 418-423.
[3]	应乔, 俞懿强, 苏俭生. 负载脱落乳牙干细胞外泌体的透明质酸可注射水凝胶的制备及其对小鼠牙周炎抗炎成骨的研究[J]. 《口腔颌面外科杂志》, 2023, 33(5): 292-297.
[4]	周新谊, 叶涛, 邱凤美. miR-503靶向作用RECK调控口腔鳞状细胞癌细胞增殖、侵袭和凋亡的机制研究[J]. 《口腔颌面外科杂志》, 2023, 33(5): 305-313.
[5]	孙昊, 林超, 马旭彤, 仲若恺, 范欣. 矿化胶原联合浓缩生长因子治疗颌骨囊肿术后骨缺损的临床研究[J]. 《口腔颌面外科杂志》, 2023, 33(5): 320-325.
[6]	刘宪光, 颜淑云, 王旭霞. 牙骨质-骨结构不良21例诊治分析[J]. 《口腔颌面外科杂志》, 2023, 33(5): 330-335.
[7]	钱虹静, 刘钰莲, 张云鹏, 师一鸣, 黄光辉, 周也然, 罗光明. 淫羊藿苷对MC3T3-E1增殖及成骨分化的影响研究[J]. 《口腔颌面外科杂志》, 2023, 33(4): 219-223.
[8]	蔡永静, 陈志方, 张薇. 下颌舌侧孔解剖特点的CBCT观察[J]. 《口腔颌面外科杂志》, 2023, 33(4): 248-253.
[9]	吴秋裕, 陈浩, 朴正国, 张君伟, 欧阳可雄. 开窗减压术联合塞治器治疗混合牙列期颌骨囊肿1例[J]. 《口腔颌面外科杂志》, 2023, 33(4): 269-271.
[10]	周涛, 王佐林. Hmcn1对MC3T3-E1细胞体外成骨分化、迁移及增殖影响的实验研究[J]. 《口腔颌面外科杂志》, 2023, 33(2): 77-82.
[11]	康献刚, 牛军强, 赵冬霞, 霍霁. 重组人源肿瘤坏死因子受体融合蛋白对大鼠下颌骨缺损的干预效果[J]. 《口腔颌面外科杂志》, 2023, 33(2): 83-88.
[12]	宋丽娜, 吴春月, 秦清岩, 楚天舒, 刘麒麟. 不同类型血管化游离腓骨瓣修复下颌骨缺损的回顾性分析[J]. 《口腔颌面外科杂志》, 2023, 33(2): 104-110.
[13]	罗容春, 韩雪, 王海丞, 朱辙文, 刘力维, 王佐林. 甲氨蝶呤对小鼠磨牙牙胚发育的影响[J]. 《口腔颌面外科杂志》, 2023, 33(1): 1-7.
[14]	郭凌燕, 吴平凡, 陈芬, 李羽, 雷振革, 陈林林. 颌骨单纯性骨囊肿的临床分析[J]. 《口腔颌面外科杂志》, 2023, 33(1): 36-41.
[15]	张庆福. 3D打印钛合金植入体下颌骨修复重建远期效果观察1例[J]. 《口腔颌面外科杂志》, 2023, 33(1): 57-61.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

双膦酸盐对大鼠颌面骨及外周骨不同来源骨髓间充质干细胞成骨分化的影响

Effect of Bisphosphonates on Osteogenic Potential of Mandibular vs. Long-bone Mesenchymal Stem Cells in Rats

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价